Evidence map›Paper›PMID 42728254›Full record

ArticleScientific reports2026

Dual-antigen AdV5 vaccines against Crimean-Congo hemorrhagic fever virus induce superior humoral and Th1-biased cellular immunity.

Alireza Hanifehnezhad, Sidika Oztop, Ece Tavukcuoglu, Yigit Tanyeri, Ekimcan Yoyler, Gokcen Gokce Tepeli, Nilay Unal, Asuman Bozkir, M Taner Karaoglu, Gunes Esendagli and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alireza Hanifehnezhad *Department of Virology, Faculty of Veterinary Medicine, Ankara University, Ankara, 06070, Turkey.ORCID 0000-0002-8183-3455
Sidika Oztop *Department of Medical Biology, Faculty of Medicine, Ankara Medipol University, Ankara, 06570, Turkey.ORCID 0000-0001-5653-6080
Ece TavukcuogluDepartment of Basic Oncology, Cancer Institute, Hacettepe University, Ankara, 06100, Turkey.ORCID 0000-0003-3344-468X
Yigit TanyeriAziz Sancar Research Centre, Health Institutes of Turkiye, Ankara, 06270, Turkey.ORCID 0000-0002-9385-259X
Ekimcan YoylerGraduate School for Health Sciences, Ankara University, Ankara, 06070, Turkey.ORCID 0009-0002-3333-8932
Gokcen Gokce TepeliDepartment of Histology and Embryology, Faculty of Medicine, Aydin Adnan Menderes University, Aydin, 09070, Turkey.ORCID 0000-0002-7303-2826
Nilay UnalDollvet Biotechnology, Sanliurfa, 63200, Turkey.ORCID 0000-0001-9969-1187
Asuman BozkirDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Ankara University, Ankara, 06560, Turkey.ORCID 0000-0002-2782-3280
M Taner KaraogluDepartment of Virology, Faculty of Veterinary Medicine, Ankara University, Ankara, 06070, Turkey.ORCID 0000-0002-9968-0813
Gunes EsendagliDepartment of Basic Oncology, Cancer Institute, Hacettepe University, Ankara, 06100, Turkey.ORCID 0000-0003-4865-2377
Ates KaraDepartment of Pediatrics, Pediatric Infectious Diseases Unit, Faculty of Medicine, Hacettepe University, Ankara, 06100, Turkey.ORCID 0000-0002-1654-3232
Hakan GurdalDepartment of Medical Pharmacology, Faculty of Medicine, Ankara University, Ankara, 06230, Turkey. hakan.gurdal@medicine.ankara.edu.tr.ORCID 0000-0003-4751-2372
Aykut OzkulDepartment of Virology, Faculty of Veterinary Medicine, Ankara University, Ankara, 06070, Turkey. ozkul@ankara.edu.tr.ORCID 0000-0001-5008-9443

Funding

Türkiye Sağlık Enstitüleri Başkanlığı 22897/28589
6 · The paper itself

Abstract

Platforms based on adenoviral vectors have proven their efficiency in developing vaccines and therefore can be considered potential candidates for immunization strategies against CCHFV. In this study, four replication-deficient recombinant human adenovirus serotype 5 (AdV5) vectors were engineered to express CCHFV antigens: a dual-antigen NP-P2A-Gc construct and monocistronic constructs for nucleoprotein (NP), glycoprotein complex precursor (GPC), and mature glycoprotein (Gc). Following GMP-compatible production and purification, vaccine candidates were evaluated in BALB/c mice (n = 4 per group) for immunogenicity and in IFNAR

Indexed as

Adenoviruses, HumanAntigens, ViralHemorrhagic Fever Virus, Crimean-CongoImmunity, CellularImmunity, HumoralTh1 CellsViral VaccinesAnimalsAntibodies, NeutralizingAntibodies, ViralFemaleGenetic VectorsHumansMiceMice, Inbred BALB CAntibodies, NeutralizingAntibodies, ViralAntigens, ViralViral VaccinesAntigenically Homologous and Heterologous Prime-boost immunizationCrimean-Congo hemorrhagic feverDual-antigen Adenovirus vector vaccineNeutralizing antibodiesProtective immunity

Identifiers

PMID42728254
PMCPMC13569847

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.